CN206526312U - Implanted prosthesis for breast augmentation - Google Patents
Implanted prosthesis for breast augmentation Download PDFInfo
- Publication number
- CN206526312U CN206526312U CN201621075399.0U CN201621075399U CN206526312U CN 206526312 U CN206526312 U CN 206526312U CN 201621075399 U CN201621075399 U CN 201621075399U CN 206526312 U CN206526312 U CN 206526312U
- Authority
- CN
- China
- Prior art keywords
- shell body
- main leaf
- riser
- transverse sheet
- vitellarium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 210000000481 breast Anatomy 0.000 title claims abstract description 33
- 230000003416 augmentation Effects 0.000 title 1
- 239000007943 implant Substances 0.000 claims abstract description 30
- 239000000835 fiber Substances 0.000 claims description 21
- 238000002347 injection Methods 0.000 claims description 16
- 239000007924 injection Substances 0.000 claims description 16
- 235000019994 cava Nutrition 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 3
- 230000006978 adaptation Effects 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 5
- 238000011049 filling Methods 0.000 abstract description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 33
- 239000000017 hydrogel Substances 0.000 description 25
- 239000000243 solution Substances 0.000 description 16
- 239000000377 silicon dioxide Substances 0.000 description 15
- 239000000499 gel Substances 0.000 description 14
- 229920001661 Chitosan Polymers 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 108010062276 T-Cell Acute Lymphocytic Leukemia Protein 1 Proteins 0.000 description 5
- 102100040365 T-cell acute lymphocytic leukemia protein 1 Human genes 0.000 description 5
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical class C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 229920001652 poly(etherketoneketone) Polymers 0.000 description 4
- 239000012266 salt solution Substances 0.000 description 4
- 229910052710 silicon Inorganic materials 0.000 description 4
- 239000010703 silicon Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- RGHHSNMVTDWUBI-UHFFFAOYSA-N 4-hydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1 RGHHSNMVTDWUBI-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical class COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
- 206010062575 Muscle contracture Diseases 0.000 description 2
- 208000034530 PLAA-associated neurodevelopmental disease Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 208000006111 contracture Diseases 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000000921 morphogenic effect Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 229920000570 polyether Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- AVPCPPOOQICIRJ-UHFFFAOYSA-L sodium glycerol 2-phosphate Chemical compound [Na+].[Na+].OCC(CO)OP([O-])([O-])=O AVPCPPOOQICIRJ-UHFFFAOYSA-L 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- RSNQKPMXXVDJFG-UHFFFAOYSA-N tetrasiloxane Chemical compound [SiH3]O[SiH2]O[SiH2]O[SiH3] RSNQKPMXXVDJFG-UHFFFAOYSA-N 0.000 description 1
- 150000003583 thiosemicarbazides Chemical class 0.000 description 1
- QQQSFSZALRVCSZ-UHFFFAOYSA-N triethoxysilane Chemical compound CCO[SiH](OCC)OCC QQQSFSZALRVCSZ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/12—Mammary prostheses and implants
Landscapes
- Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Prostheses (AREA)
Abstract
The utility model discloses a breast implant, belonging to the field of face-lifting apparatus. The utility model discloses a breast implant, which comprises an outer shell, the shell body is hollow cavity, the shell body outline is human breast shape, the shell body bottom is inside sunken, the middle part is equipped with growing zone in the shell body, inside the shell body, growing zone both sides are equipped with the filling district. The utility model discloses a breast implant has can perfect adaptation every individuality, has good feeling and form, has high security simultaneously, and resilience performance is good, non-deformable, and histocompatibility is good, can avoid human tissue rejection and attack, reduces the possibility that the implant causes the complication, and to the human body innoxic side effect, can make the implanted person obtain the characteristics of feeling the same body with the primary tissue.
Description
Technical field
The utility model is related to a kind of lift face apparatus, particularly a kind of breast prosthetic implant.
Background technology
Prosthese is enlarged the bosom, and material category is more, and classification is different, can be divided into Silica hydrogel packed type and life by its intracapsular tolerant difference
Manage salt solution filling type etc.;It can be divided into injection type by its application method and insert type, general Silica hydrogel packed type is to insert type, physiology
Salt solution filling type is injection type;In addition, there are the materials such as superseded atoleine, liquid-state silicon gel, Elipten AG, these
Material can cause many severe complications, with toxic side effect, prohibited and used.It is existing to enlarge the bosom material still
Using Silica hydrogel and physiological saline as main flow, although biological respinse caused by Silica hydrogel and physiological saline is minimum, compared with other materials more
Plus it is soft, naturally, still physiological saline has very strong also body-sensing, easy to leak, the effect of mamaplasty is difficult to maintain, meeting after salt solution oozes out
Breast deflating phenomenon is caused, profile is influenceed.It is not good enough with respect to form for silicon gel artificial body and feel, and put for a long time in human body
Putting can make the intracapsular portion of salt solution easily produce mould;And the capsule contracture incidence of Silica hydrogel is higher, while having immunity connective
The sick and carcinogenic risk of tissue, and Silica hydrogel generally using so for many years after, complication gradually shows, it is known that complication master
Will be by granuloma, simultaneously as Silica hydrogel is prefabricated implant, shapes and sizes are usually the fixed dimension of standard, it is impossible to
Perfectly agreed with each individual, and formality complexity is customized according to each individual, it is with high costs;No matter but which kind of
Implant, can not all make it that being implanted human body obtains and basic stitch identical body-sensing.
Utility model content
Utility model purpose of the present utility model is:Perfect it can be adapted to there is provided one kind for above-mentioned problem
Each individual, with excellent handle and form, while having high security, rebound performance is good, is unlikely to deform, histocompatbility
It is good, tissue can be avoided to reject and attack, reduce the possibility that implant triggers complication, human body is had no toxic side effect,
Enable to be implanted the breast prosthetic implant that people obtains body-sensing identical with basic stitch.
The technical solution adopted in the utility model is as follows:
A kind of breast prosthetic implant of the present utility model, including shell body, the shell body are hollow cavity, the shell
External profile is in human breast shape, and the shell body bottom caves inward, and middle part is provided with vitellarium in the shell body, described
Inside shell body, vitellarium both sides are provided with fill area, and the fill area is provided with injection zone, and the injection zone is in fill area
Portion, the injection zone has hollow cavity, and the injection zone outer wall is made up of permeable membrane.
By adopting the above-described technical solution, outer housing bottom set depressed area, can implant implantation human body after,
Rest area is provided for original breast tissue, can be avoided after implant is taken out, original breast tissue shape is destroyed,
The space that may be grown is provided for intramammary histocyte, it is ensured that the original free degree of tissue, pass through injection zone simultaneously
The size of fill area can be adjusted, so as to meet the demand of different crowd;And direct injection may be to fill area
Shape cause change, by the slow infiltration of injection zone, ensure that the gel for newly injecting slowly with former fill area
Gel is combined, so as to ensure the perfect shape of fill area.
With connecting at the top of shell body at the top of a kind of breast prosthetic implant of the present utility model, the vitellarium, the vitellarium
Interior to be provided with some stators and some fibre pipes, the stator surface is evenly equipped with some through holes, and the fibre pipe passes through through hole
Stator is connected.
By adopting the above-described technical solution, can be capillary, nerve fibre tip by stator and fibre pipe
Deng offer growing space, it is ensured that the blood circulation of basic stitch, so as to ensure the connection of basic stitch body and overlaying skin, so as to ensure
Implant can still bring original body-sensing.
A kind of breast prosthetic implant of the present utility model, the stator includes main leaf, and the main leaf is vertically located at
In the middle part of vitellarium, the main leaf surface is evenly equipped with three row through holes;The main leaf both sides are provided with two transverse sheets in the horizontal direction, each
The transverse sheet surface is evenly equipped with an exhausting hole;Both sides are provided with two risers below the main leaf, and each described riser surface is uniform
There is a row through hole.
By adopting the above-described technical solution, the through hole arranged by different directions ensure that fibre pipe is staggered,
Growth closest to the original capillary of human body, nerve fibre tip is arranged.
A kind of breast prosthetic implant of the present utility model, the transverse sheet level height is less than the level height on main leaf top, institute
State the level height that transverse sheet level height is more than riser top;The top of the main leaf and shell body interval, the bottom of the main leaf
Portion and shell body bottom connection, two ends and the vitellarium inwall interval of the transverse sheet, bottom and the shell body bottom of the riser
Connect, the main leaf, transverse sheet and riser are spaced.
A kind of breast prosthetic implant of the present utility model, the surface area of the transverse sheet is the 40% of main leaf surface, the riser
Surface area is the 35% of main leaf surface.
A kind of breast prosthetic implant of the present utility model, the fibre pipe is distributed in the both sides of main leaf, each described fiber
Pipe connects shell body bottom with top through riser, transverse sheet and/or main leaf, and the fibre pipe per side has three kinds through side respectively
Formula, including sequentially pass through transverse sheet and riser from top to bottom, up to sequentially passes through down main leaf, transverse sheet and riser, and from top to bottom according to
It is secondary to pass through main leaf and riser.
A kind of breast prosthetic implant of the present utility model, the shell body is by 27 parts of polyethers of mass parts, 13 parts of modified silica-gels, 17 parts of prestox rings
Tetrasiloxane, 8 parts of methyl methacrylates, 55 parts of Silica hydrogels and 3 parts of sodium carboxymethyl starches are constituted, and the thickness of the shell body is
0.8cm。
By adopting the above-described technical solution, shell body is using Silica hydrogel as base material, modification is carried out and has reduced Silica hydrogel bag
Film contracture incidence, adds the rebound performance of shell body, is unlikely to deform, being capable of long term shape retention, secondary work nontoxic to human body
With the granulomatous occurrence probability of reduction.
A kind of breast prosthetic implant of the present utility model, the fibre pipe is by 6 parts of foam silicon carbons of mass parts, and 23 parts are gathered in oneself
Ester, 17 parts of PLAs, 37 parts of PEKKs, 32 parts of fat stem cell-protein hydrogels and 3 parts of dilute citric acid compositions, it is described poly-
Caprolactone, PLA and PEKK are cross-linked to form porous support, and the porosity of the porous support is 43.8%, the fat
In stem cell-protein hydrogel, protein hydrogel is Nano chitosan BMP, and the pH of the protein hydrogel is 6.4,
The fat stem cell:Chitosan:Bone morphogenic proteins quality compares 2.3:17.2:6.
By adopting the above-described technical solution, fat stem cell can live for organization survival, to provide angiogenic growth thin for growth
Born of the same parents, after cell forms stable structure, hydrogel structure is to be metabolized decomposition, its position being originally present, and just turns into and is available for
The cavity that blood vessel extends and developed.
It is described gel filled by matter filled with gel filled in a kind of breast prosthetic implant of the present utility model, the fill area
Measure 55 parts of agaroses of part, 13 parts of chitosans, 72 parts of Silica hydrogels, 19 parts of N- carboxymethyl chitosans and 7 parts of carboxymethyl cellulose compositions.
By adopting the above-described technical solution, packing material can reduce the risk that Silica hydrogel induces complication, have simultaneously
There is good feel, material softness is close to tissue, and the adaptation that can carry out shape as needed in implantation changes, so that
Reach each individual demand of adaptation, gel filled condensation performance is good, when occurring alteration of form, be not in hole,
Crack etc..
In summary, by adopting the above-described technical solution, the beneficial effects of the utility model are:
1st, each individual perfect can be adapted to, with excellent handle and form, while having high security, rebound performance
It is good, it is unlikely to deform, histocompatbility is good, tissue can be avoided to reject and attack, reduce that implant triggers complication can
Energy property, has no toxic side effect to human body, enables to be implanted people's acquisition body-sensing identical with basic stitch.
2nd, reduction Silica hydrogel induces the risk of complication, while have good feel, material softness close to tissue,
The adaptation that shape can be carried out as needed in implantation changes, so that each individual demand of adaptation is reached, it is gel filled
Condensation performance it is good, occur alteration of form when, be not in hole, crack etc..
Brief description of the drawings
Fig. 1 is a kind of breast prosthetic implant structural representation.
Marked in figure:1 is shell body, and 2 be vitellarium, and 3 be fill area, and 4 be main leaf, and 5 be transverse sheet, and 6 be riser.
Embodiment
Below in conjunction with the accompanying drawings, the utility model is described in detail.
In order that the object, technical solution and advantage of utility model are more clearly understood, below in conjunction with drawings and Examples,
The utility model is further elaborated.It should be appreciated that specific embodiment described herein is only to explain this
Utility model, is not used to limit the utility model.
Embodiment 1
As shown in figure 1, a kind of breast prosthetic implant, including shell body 1, shell body 1 is hollow cavity, the foreign steamer of shell body 1
Exterior feature is in human breast shape, and the bottom of shell body 1 caves inward, and middle part is provided with inside vitellarium 2, shell body 1 in shell body 1, raw
The long both sides of area 2 are provided with fill area 3, and fill area 3 is provided with injection zone 7, and injection zone is inside fill area 3, and injection zone 7 has hollow
Cavity, the outer wall of injection zone 7 is made up of permeable membrane.The top of vitellarium 2 connects with the top of shell body 1, if provided with solid in vitellarium 2
Stator and some fibre pipes, stator surface are evenly equipped with some through holes, and fibre pipe connects stator through through hole.Stator bag
Main leaf 4 is included, main leaf is vertically located at the middle part of vitellarium 2, and the surface of main leaf 4 is evenly equipped with three row through holes;The both sides of main leaf 4 are along level
Direction is provided with two transverse sheets 5, and each described transverse sheet surface is evenly equipped with an exhausting hole;The lower section both sides of main leaf 4 are provided with two risers 6, often
One riser surface is evenly equipped with a row through hole.Transverse sheet level height is less than the level height on main leaf top, and transverse sheet level is high
Level height of the degree more than riser top;The top of main leaf is spaced with shell body 1, bottom and the bottom connection of shell body 1 of main leaf,
The two ends of transverse sheet and the inwall interval of vitellarium 2, bottom and the bottom connection of shell body 1 of riser, main leaf, transverse sheet and riser are to each other
Every.The surface area of transverse sheet is the 40% of main leaf surface, and the surface area of riser is the 35% of main leaf surface.Fibre pipe is distributed in main leaf
Both sides, each fibre pipe connects the bottom of shell body 1 with top through riser, transverse sheet and/or main leaf, the fibre pipe per side
There are three kinds to pass through mode respectively, including sequentially pass through transverse sheet and riser from top to bottom, up to sequentially pass through main leaf down, transverse sheet and perpendicular
Piece, and main leaf and riser are sequentially passed through from top to bottom.
Shell body 1 is by 27 parts of polyethers of mass parts, 13 parts of modified silica-gels, 17 parts of octamethylcy-clotetrasiloxanes, 8 parts of methyl methacrylates, 55 parts of Silica hydrogels
With 3 parts of sodium carboxymethyl starch compositions, the thickness of shell body 1 is 0.8cm.Fibre pipe is by 6 parts of foam silicon carbons of mass parts, and 23 parts are gathered
Caprolactone, 17 parts of PLAs, 37 parts of PEKKs, 32 parts of fat stem cell-protein hydrogels and 3 parts of dilute citric acid compositions, gather
Caprolactone, PLA and PEKK are cross-linked to form porous support, and the porosity of porous support is 43.8%, fat stem cell-egg
In plain boiled water gel, protein hydrogel is Nano chitosan BMP, and the pH of protein hydrogel is 6.4, fat stem cell:Shell
Glycan:Bone morphogenic proteins quality compares 2.3:17.2:6.It is gel filled by 55 parts of fine jades of mass parts filled with gel filled in fill area 3
Lipolysaccharide, 13 parts of chitosans, 72 parts of Silica hydrogels, 19 parts of N- carboxymethyl chitosans and 7 parts of carboxymethyl cellulose compositions.
Embodiment 2
PolyethersSynthesize by the following method:
At room temperature 69.5g is added into configuration mechanical agitation, reflux condensing tube, thermometer, the four-hole bottle of dropping funel
(0.2mol)Hexachlorocyclotriph,sphazene and 200mL tetrahydrofurans, after stirring is dissolved after solid whole portion, are added dropwise dissolved with 69.7g phenol
The tetrahydrofuran solution of sodium;After being added dropwise to complete, back flow reaction 3h is filtered and is collected filtrate;A four-hole bottle separately is taken, is sequentially added
146.5g parahydroxyben-zaldehydes, 300mL tetrahydrofurans and 414.6g Anhydrous potassium carbonates, are stirred completely molten to parahydroxyben-zaldehyde
Xie Hou, is added dropwise the filtrate of above-mentioned gained thereto, is added dropwise to complete rear back flow reaction 6h, is filtered after the completion of reaction, collects after filtrate
It is concentrated into the 1/4 of original volume;Then, remaining mixture is slowly put into frozen water, quick stirring is until faint yellow creamy liquid
Body is all separated out;Successively with 10% KOH solution, water, methanol detergent cream grease, until all solids are separated out;Vacuum after suction filtration
Dry to weight, obtain pale yellow powder shape solid.
Embodiment 3
Modified silica-gelSynthesize by the following method:
20g silica gel is added in concentrated hydrochloric acid, 6h is heated to reflux, is washed with deionized to neutrality, 16h is dried at 180 DEG C
After obtain activated silica gel.8g activated silica gels are added in the toluene solvant that 80mL is dried, 8mL3- chloropropyls are slowly added dropwise thereto
Triethoxysilane, under nitrogen protection, back flow reaction 12h, filtering, product are repeatedly washed with toluene, ethanol and ether successively,
6h is dried in vacuo at 80 DEG C.6g thiosemicarbazides is added in 100mL ethanol, heating dissolves it, add 8g the said goods, backflow
8h is reacted, filtering is repeatedly washed with ethanol and hot water, is dried in vacuo 12h at 80 DEG C, obtains target product.
Embodiment 4
Fat stem cell-protein hydrogel is prepared by the following method:
BMP is wrapped in Nano chitosan solution first, 2 ~ 4h of sealing and standing, under magnetic stirring, by than
Fat stem cell is included in solution by example, 56% sodium β-glycerophosphate is added dropwise in chitosan solution, solution is gradually muddy,
Continue to be added dropwise to solution in limpid state, stop being added dropwise, add 0.1mmol/L second acid for adjusting pH to 7.2.Filtration sterilization, it is close
Envelope, obtains fat stem cell-protein hydrogel.
Preferred embodiment of the present utility model is the foregoing is only, it is all at this not to limit the utility model
Any modifications, equivalent substitutions and improvements made within the spirit and principle of utility model etc., should be included in the utility model
Protection domain within.
Claims (6)
1. a kind of breast prosthetic implant, it is characterised in that:Including shell body(1), the shell body(1)It is described for hollow cavity
Shell body(1)Outline is in human breast shape, the shell body(1)Bottom caves inward, the shell body(1)Interior middle part is set
There is vitellarium(2), the shell body(1)Inside, vitellarium(2)Both sides are provided with fill area(3), the fill area(3)Provided with note
Penetrate area(7), the injection zone is located at fill area(3)Inside, the injection zone(7)With hollow cavity, the injection zone(7)Outside
Wall is made up of permeable membrane.
2. a kind of breast prosthetic implant as claimed in claim 1, it is characterised in that:The vitellarium(2)Top and shell body(1)
Top connects, the vitellarium(2)Interior to be provided with some stators and some fibre pipes, the stator surface is evenly equipped with some logical
Hole, the fibre pipe connects stator through through hole.
3. a kind of breast prosthetic implant as claimed in claim 2, it is characterised in that:The stator includes main leaf(4), the master
Piece is vertically located at vitellarium(2)Middle part, the main leaf(4)Surface is evenly equipped with three row through holes;The main leaf(4)Both sides edge
Horizontal direction is provided with two transverse sheets(5), each described transverse sheet surface is evenly equipped with an exhausting hole;The main leaf(4)Lower section both sides are set
There are two risers(6), each described riser surface is evenly equipped with a row through hole.
4. a kind of breast prosthetic implant as claimed in claim 3, it is characterised in that:The transverse sheet level height is less than main leaf top
Level height, the transverse sheet level height be more than riser top level height;The top of the main leaf and shell body(1)Between
Every the bottom of the main leaf and shell body(1)Bottom connection, the two ends and vitellarium of the transverse sheet(2)Inwall interval, it is described perpendicular
The bottom of piece and shell body(1)Bottom connection, the main leaf, transverse sheet and riser are spaced.
5. a kind of breast prosthetic implant as described in claim 3 or 4, it is characterised in that:The surface area of the transverse sheet is main leaf table
The 40% of face, the surface area of the riser is the 35% of main leaf surface.
6. a kind of breast prosthetic implant as claimed in claim 5, it is characterised in that:The fibre pipe is distributed in the both sides of main leaf,
Each described fibre pipe passes through riser, transverse sheet and/or main leaf by shell body(1)Bottom is connected with top, the fiber per side
Pipe has three kinds to pass through mode respectively, including sequentially passes through transverse sheet and riser from top to bottom, up to sequentially passes through main leaf down, transverse sheet and
Riser, and main leaf and riser are sequentially passed through from top to bottom.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201621075399.0U CN206526312U (en) | 2016-09-24 | 2016-09-24 | Implanted prosthesis for breast augmentation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201621075399.0U CN206526312U (en) | 2016-09-24 | 2016-09-24 | Implanted prosthesis for breast augmentation |
Publications (1)
Publication Number | Publication Date |
---|---|
CN206526312U true CN206526312U (en) | 2017-09-29 |
Family
ID=59921276
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201621075399.0U Expired - Fee Related CN206526312U (en) | 2016-09-24 | 2016-09-24 | Implanted prosthesis for breast augmentation |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN206526312U (en) |
-
2016
- 2016-09-24 CN CN201621075399.0U patent/CN206526312U/en not_active Expired - Fee Related
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8070808B2 (en) | Variable cohesive gel form-stable breast implant | |
CN102325507A (en) | Silicone implant with expandable and/or interfitting compartments, coated or uncoated with polyurethane foam made of castor oil and/or hydroxyapatite, with anchoring tabs or strings | |
CN106264786B (en) | A kind of chest enhancement prosthesis | |
JP3224441U (en) | Breast prosthesis | |
GB2046098A (en) | Prosthetic device | |
CN109276353A (en) | The whole breast prosthesis of volume-tunable | |
CN206526312U (en) | Implanted prosthesis for breast augmentation | |
CN100342807C (en) | Postoperative bilateral augmentation mammaplasty brassiere | |
CN206414370U (en) | A kind of breast prosthetic implant | |
CN206414371U (en) | A kind of chest enhancement prosthesis | |
CN106377342B (en) | A kind of breast prosthetic implant | |
US20160228236A1 (en) | Breast implant support device with large back surface area | |
US20130150962A1 (en) | Mammary prosthesis filled with expanded polymer microspheres | |
CN106267373A (en) | One is enlarged the bosom with implanting prosthese | |
WO2002091331B1 (en) | Breast cancer detection | |
Hodgkinson | Buckled upper pole breast style 410 implant presenting as a manifestation of capsular contraction | |
CN106924090A (en) | A kind of preparation and application of the immobilized lysozyme toothpaste of multistage hole bioactive glass | |
CN207995927U (en) | A kind of bionical brassiere with natural disinfection health care breast protecting function | |
CN209059552U (en) | A kind of assembled personalized artificial centrum | |
CN208676877U (en) | A kind of tender orthocephaly maize fragrance pillow of newborn | |
CN201585419U (en) | Bras for breast cancer patients and breast malposition users | |
CN210932045U (en) | Artificial breast implant | |
CN100421682C (en) | Luhuapan soft capsule and its prepn process | |
CN220046188U (en) | Buttock silica gel prosthesis | |
RU2202311C2 (en) | Method for preparing overlappings onto mammary glands in women |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20170929 |